CONTRAD-SWISS
Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino to bring to the market effective biomedical remedies unlike any other.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005031/en/
SIGMOLECS® Technology was conceived and engineered by Dr Serrentino exclusively for Contrad Swiss.
SIGMOLECS® uses the highest bioavailable signaling molecules to summon and target biological pathways for precise programming at the cellular level. The result is like a program code of the cells, deploying them to organize into specific patterns. SIGMOLECS® talks to the cells in their language.
ACTV8SKN®
– Actuator - contains the exclusive SIGMOLECS®
Technology.
ACTV8SKN®
is an odorless fluid gel of peptide-bonded amino acids, specifically engineered for a complete signaling spectrum that awakens cell cycles of the skin. It can be used in clinic to enhance procedures or dispensed to patients as a follow up take-home product. Easy to use, a few drops of ACTV8SKN®
to cleansed face. The fluid gel will absorb as soon as it is spread.
Information on the development, novel characteristics of SIGMOLECS® Technology and clinical data supporting the long-lasting efficacy of the most advanced regenerative cosmetic available today, can be requested. www.contrad.ch
About Contrad Swiss
Contrad Swiss is the most innovative pharmaceutical corporation specialized in OTC, medical devices, functional cosmetics and dietary supplements. The innovation can be expressed in the formula, in a new way of administration or a novel application. All the products are respected for their solid scientific support and they carry the consumer recognition of quality and convenience.
About Dr JO Serrentino
M.Sc; DVM; Ph.D FAARM; DABRM. Master’s in Biochemistry; Veterinarian; Doctorate in clinical ecology/environmental medicine. Fellow of the American Academy of Regenerative Medicine; Diplomat of the American Board of Regenerative Medicine.
Extensive expertise in the following areas:
- Protein sequencing and clones for biological new medicine;
- Peptide inclusion for medicine;
- Use of cytokines in medicine and therapy and as pathophysiological markers.
- Biological markers for diagnostics; targeting and research& development;
- Carrier formulations for enhanced absorption of active principles; formulating, assessment and/or amendment;
- Molecular manipulation for enhanced biological properties esp. with protein (cytokine) and gene therapy;
- Metabolic Syndromes and Energy Metabolism;
- Stem cell extenders and methodologies for clinical application;
- Orthopaedic biologicals for clinical application in Regenerative Medicine.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190626005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™6.6.2025 10:00:00 CEST | Press release
Brand Returns “Bring Home The Bud” Campaign, Debuts New Film Set to AC/DC’s “Thunderstruck” to Remind Fans that Bud is the Beer of Celebration Throughout the Tournament Today, Budweiser (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) unveils its new global platform “Celebration in the Making” and full campaign details as the Official Global Beer Sponsor of the FIFA Club World Cup 2025™. This summer, as football supporters around the globe bring their energy to the groundbreaking tournament, Budweiser will be there to elevate celebrations at every stage – from the opening touch to the final whistle, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606379419/en/ Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™ To inspire celebrations from the start, Budweiser is officially kicking off the platform with a new film set to an iconic score, and announces the return of its
SES Announces Appointment of New CFO6.6.2025 08:30:00 CEST | Press release
Elisabeth Pataki, a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies, will strengthen SES’s Leadership Team as new CFO SES today announced its Board of Directors has appointed Elisabeth (Lisa) Pataki as Chief Financial Officer (CFO), effective 16 June 2025. Lisa is a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies with strong background in company transformation and investment strategies. She will succeed Sandeep Jalan who has been SES’s CFO since May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605243814/en/ Lisa Pataki The SES Board acknowledges Sandeep’s contribution to SES and wishes him success in future endeavours. Lisa will work closely with Sandeep to ensure a smooth handover before he leaves on 31 July 2025. “I would like to thank
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years6.6.2025 07:00:00 CEST | Press release
New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its lasting impact across multiple clinical and patient reported outcomes including itch and skin lesions1 Results build on data from the phase III ARCADIA program, showing Nemluvio’s consistent safety profile and sustained and increased improvements in efficacy outcomes in atopic dermatitis patients during prolonged treatment up to two years1,2 Two-year data from a long-term extension study of Nemluvio in prurigo nodularis will also be presented later in June at the International Congress of Dermatology Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sust
BGO Announces US$5.1 Billion Capital Raise for Its Asia Value-Add Real Estate Strategy, Marking Largest Closed-End Fundraise in Firm’s History5.6.2025 22:00:00 CEST | Press release
BGO today announced the final close of BentallGreenOak Asia IV (“BGO Asia Fund IV” or the “Fund”), its flagship Asia-focused value-add real estate strategy, raising over US$5.1 billion in total capital commitments for the Fund and co-investment sidecars. The Fund represents the largest closed-end capital raise in BGO’s history, underscoring the firm’s history and reputation as a premier global real estate investment manager in Asian markets. BGO Asia Fund IV targets value-add opportunities in office, hospitality, and logistics assets across Japan, South Korea, Australia, and Singapore. Japan represents a central pillar of our investment strategy, driven by regulatory reforms and corporate governance shifts that are catalyzing an estimated US$3 trillion in non-core asset divestitures. “Japan is undergoing a profound transformation, and we see strong, sustained tailwinds across the region,” said Fred Schmidt, Managing Partner and Chairman of Asia, BGO. “Tokyo is one of the world’s larges
PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 19:00:00 CEST | Press release
PIF joins inaugural FIFA Club World Cup™ ahead of kick-off on June 14 in Miami The partnership expands PIF’s global footprint in sports and reflects a shared commitment with FIFA to fuel growth and engagement in football FIFA Club World Cup 2025™ will make history, redefining club football and bringing 32 of the world’s best clubs together for the first time PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom